Every biotech and drug company uses the Monday morning kick-off of the J.P. Morgan Healthcare Conference to announce some type of corporate update or announcement. It doesn't really matter if the news is relevant or not, what's important is the stock-promoting publicity that comes from having a press release "attached" to the JPM confab.
Even better is when a company can glom onto a hot biotech trend!
Here are five absolute worst PR panders committed by drug companies this week:
Oh man, kudos to the Agenus employee/stock tout who managed to get "checkpoint inhibitor" into the press release headline.
The lead 'graph is just as manipulative...er... I mean great...
Agenus Inc., a biotechnology company developing novel immune system activating treatments for cancers and infectious diseases, today announced initiation of a randomized Phase 2 trial with Prophage for melanoma, and Bristol-Myers Squibb's Yervoy (ipilimumab) for the treatment of Stage III and IV metastatic melanoma. The combination has the potential to trigger a more effective immune response against the tumor than Yervoy alone.
Wow! Bristol-Myers Squibb (BMY) -- the hot-shit cancer-immunotherapy company -- is partnering with tiny Agenus??!?!
Um... no, Bristol is not doing any such thing, which we learn in the third paragraph of Agenus' press release:
The Phase 2, randomized, open label, single-center, investigator-sponsored trial is designed to evaluate the safety, feasibility and immunogenicity of the combination of Prophage vaccine and Yervoy with or without low dose cyclophosphamide (a chemotherapy agent used in this study as an immunomodulator of regulatory cells) in 25 patients with unresectable Stage III or IV metastatic melanoma. The trial will be conducted at the University of Texas Health Science Center at Houston and led by clinical investigator Jorge Quesada, M.D.
An investigator-sponsored clinical trial. Oh... never mind.
NASH. Check. "Positive Results." Check. Mice? Shut the f--k up.
Wait. This "news" doesn't seem so newsy. Didn't I read about the start of this brain cancer study previously? Let me check...
Yes! On November 20, 2013:
For an added laugh, check out the quote from CytRx CEO Steve Kriegsman in this week's do-over press release, claiming that a aldoxorubicin i.e. me-too doxorubicin could qualify for FDA "breakthrough therapy" designation.
Jim Bianco: Reversion to the mean.
How does one go about re-acquiring rights to cancer drugs that never left your possession in the first place?
I have a source at the NSA who provided me with a transcript of the call between Cell Therapeutics and Novartis (NVS). Here's how it went:
Cell Therapeutics: Hi Novartis! How are you?
Novartis: Who is this?
Cell Therapeutics: It's Cell Therapeutics, your partner on Pixuvri and Opaxio. We're wondering if we could get our drugs back.
Novartis: Pixuvri? Opaxio? I'm sorry, who is this again?
Cell Therapeutics: Never mind. Have an excellent day!
I suspect Sunesis and Cell Therapeutics were in cahoots prior to the start of the JPM conference. Their respective bullshit PRs are remarkably similar.
In this cases, Sunesis "expands" its pipeline when Biogen Idec and Takeda decide to return two cancer drugs to the company.
Sunesis gets extra credit for actually holding a conference call to discuss it's non-deal deal.
-- Reported by Adam Feuerstein in Boston.
Follow Adam Feuerstein on Twitter.
10/14/15 - 11:47 AM EDT
05/19/15 - 04:42 PM EDT
05/19/15 - 12:48 PM EDT
05/18/15 - 08:06 AM EDT
05/05/15 - 02:43 PM EDT
05/03/16 - 14:00 PM EDT
05/03/16 - 11:00 AM EDT
05/03/16 - 08:17 AM EDT
05/03/16 - 07:58 AM EDT
05/03/16 - 07:40 AM EDT
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
Chris Versace, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.
Master swing trader Alan Farley uses his sophisticated software screens to review thousands of stocks each day for you, to find just the handful that meet his demanding criteria.